Liz Kelly

Efficacy and Safety of Brexpiprazole for the Treatment of Borderline Personality Disorder: a 12-Week, Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

Abstract: Background: Atypical antipsychotics may be efficacious in the treatment of borderline personality disorder (BPD). This double-blind, Phase 2 study (NCT04100096) evaluated the ef...

Liz Kelly ;

Maia Miguelez ;

01/19/2023

Safety and Tolerability of Brexpiprazole for the Treatment of Borderline Personality Disorder: a 12-Week, Flexible-Dose, Open-Label Extension Study

Abstract: Background: Atypical antipsychotics may be efficacious in the treatment of borderline personality disorder (BPD). This study assessed the safety, tolerability and efficacy of br...

Liz Kelly ;

Maia Miguelez ;

01/19/2023

Effects of Adjunctive Brexpiprazole on Patient Life Engagement in Major Depressive Disorder: A Phase 4, Open-Label, Interventional Study

Abstract: Background: Patient life engagement is a broad term describing positive health aspects across four domains (emotional, physical, social, cognitive). The 10-item Inventory of Dep...

Erin MacKenzie , PhD;

Liz Kelly ;

01/19/2023

Efficacy of Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Partial Response to Antidepressant Treatment: a Post Hoc Analysis of Three Randomized Studies

Abstract: Background: Approximately 50% of patients with major depressive disorder (MDD) have unresolved symptoms of depression on antidepressant treatment (ADT), which are associated wit...

Michael Thase , MD;

Liz Kelly ;

01/19/2023

Efficacy of Adjunctive Brexpiprazole in Patients With Unresolved Symptoms of Depression on Antidepressant Treatment Who Are Early in the Disease Course: a Post Hoc Analysis of Four Randomized Studies

Abstract: Background: Approximately 50% of patients with major depressive disorder (MDD) have unresolved symptoms of depression on antidepressant treatment (ADT). For such patients, early...

Michael Thase , MD;

Liz Kelly ;

01/19/2023

Efficacy, Safety and Tolerability of Brexpiprazole for the Treatment of Agitation in Alzheimer’s Dementia: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial

Abstract: Background: Agitation is common in Alzheimer’s dementia, and one of the most stressful aspects of care. The aim of this study was to confirm the efficacy, safety and tolerabilit...

Daniel K. Lee , DPM;

Liz Kelly ;

01/19/2023